Last reviewed · How we verify
Capecitabine and Mitomycin C
Capecitabine is a thymidylate synthase inhibitor, and Mitomycin C is an alkylating agent.
Capecitabine is a thymidylate synthase inhibitor, and Mitomycin C is an alkylating agent. Used for Colorectal cancer, Breast cancer.
At a glance
| Generic name | Capecitabine and Mitomycin C |
|---|---|
| Also known as | Capecitabine (Xeloda), Mitomycin C (Mutamycin) |
| Sponsor | Croatian Cooperative Group for Clinical Research in Oncology |
| Drug class | Antineoplastic agents |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Capecitabine is converted to 5-fluorouracil, which inhibits thymidylate synthase. Mitomycin C cross-links DNA, preventing DNA replication and transcription.
Approved indications
- Colorectal cancer
- Breast cancer
Common side effects
- Hand-foot syndrome
- Diarrhea
- Fatigue
- Nausea
- Vomiting
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study (PHASE2)
- HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer (PHASE2)
- Adaptive Radiation in Anal Cancer (NA)
- REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation (PHASE2, PHASE3)
- Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11) (NA)
- Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |